Results 111 to 120 of about 109,707 (304)

Predicting One-Year Deaths and Major Adverse Vascular Events with the Controlling Nutritional Status Score in Elderly Patients with Non-ST-Elevated Myocardial Infarction Undergoing Percutaneous Coronary Intervention. [PDF]

J Clin Med, 2021
Kalyoncuoğlu M, Katkat F, Biter HI, Cakal S, Tosu AR, Can MM.   +5 more
europepmc   +1 more source

Serotonin reuptake inhibitors and cardiovascular disease [PDF]

, 2005
Selective serotonin re-uptake inhibiting drugs (SSRIs) are widely used for endogenous depression. In addition to depleting the nerve terminals of serotonin they also lower blood platelet serotonin levels.
Belcher, P.R., Drake-Holland, A.J., Noble, M.   +2 more
core   +1 more source

Allosteric modulation of zinc speciation by fatty acids [PDF]

Background: Serum albumin is the major protein component of blood plasma and is responsible for the circulatory transport of a range of small molecules that include fatty acids, hormones, metal ions and drugs.
Barnett, James P., Dr., Blindauer, Claudia A., Kassaar, Omar, Khazaipoul, Siavash, Martin, Esther M., Sadler, P. J., Stewart, Alan J. S.   +6 more
core   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

Amyloid β1‐40 Predicts Long‐Term Mortality Rate in Patients With Acute Myocardial Infarction

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Amyloid β1‐40 (Aβ1‐40) contributes to atherosclerosis, being involved in plaque formation and destabilization. The prognostic role of Aβ1‐40 in patients with acute myocardial infarction is currently limited to non–ST‐segment–elevation ...
Aneta Aleksova, Alessandra Lucia Fluca, Alessandro Pierri, Giulia Barbati, Antonio Paolo Beltrami, Laura Padoan, Enzo Merro, Maria Marketou, Donna Zwas, Stefano D'Errico, Gianfranco Sinagra, Milijana Janjusevic   +11 more
doaj   +1 more source

C-reactive protein as a predictor of adverse outcome in patients with acute coronary syndrome

Heart Views, 2012
Background and Objectives: The acute-phase reactant C-reactive protein (CRP) has been shown to reflect systemic and vascular inflammation and to predict future cardiovascular events. The objective of this study was to evaluate the prognostic value of CRP
A S Sheikh, S Yahya, N S Sheikh, A A Sheikh   +3 more
doaj   +1 more source

The combinational effect of cardiac and biochemical markers in diabetic patients with cardiovascular disease [PDF]

, 2011
Background: Clinicopathological correlations, as well as several angiographic studies, suggest that diabetic patients have more extensive atherosclerotic disease, affecting the coronary arteries in particular.
Palanisamy Pasupathi, YY Rao, Farook J, Sathiyamoorthy Subramaniyam, Babu Shankar Ponnusha, Athimoolam Ambika, Int J Cur Bio Med Sci.
core  

Long‐term cardiovascular outcomes of immune checkpoint inhibitor‐related myocarditis: A large single‐centre analysis

ESC Heart Failure, Volume 12, Issue 2, Page 1237-1245, April 2025.
Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri, Ahmad Gharaibeh, Lubika Nkashama, Abdelrahman Abushouk, Osama Abushawer, Amir Mehdizadeh‐Shrifi, Bianca Honnekeri, Cassandra Calabrese, Venu Menon, Pauline Funchain, Patrick Collier, Diego Sadler, Rohit Moudgil   +12 more
wiley   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source